Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Clinical trial NCT05158296 · TERMINATED
Trial details
- NCT number
- NCT05158296
- Sponsor
- Laboratoires Thea
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2022-10-12
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.